KMID : 0360320010330050392
|
|
Journal of Korean Cancer Research Association 2001 Volume.33 No. 5 p.392 ~ p.397
|
|
The Reliability of Histoculture Drug Response Assay ( HDRA ) in Chemosensitivity Tests for Breast Cancer
|
|
°ÈñÁØ/Hee Joon Kang
°íâ´ë/À±È£¼º/±è¹®º¸/¾È¼¼Çö/Chang Dae Ko/Ho Sung Yoon/Moon Bo Kim/Sei Hyun Ahn
|
|
Abstract
|
|
|
PURPOSE: Cancers are highly individual in their response to chemotherapy, however attempts to predict tumor response to drugs using in vitro cell culture have largely failed. A new technology, the histoculture drug response assay (HDRA), appears to have solved many previous problems. The purpose of this study is to evaluate the reliability of HDRA in a chemosensitivity test for breast cancer.
MATERIALS AND METHODS: Tumor specimens from breast cancer patients were evaluated by HDRA using different chemotherapeutic agents. Each specimen was tested using a blind method in order to determine the reproducibility of HDRA results for the same tissue and with a triplicated assay in order to determine reproducibility by different examiners. The evaluative power of this assay and the chemosensitivity of drugs for each specimen was determined.
RESULTS: Specimens of 92.9% (65/70) were successfully cultured and evaluated for chemosensitivity. The reproducibility of HDRA for the same tissue was 75% (100% agreement) and 100% (over 70% agreement), respectively. And the reproducibility by different examiners was 78.9% (100% agreement) and 94.7% (over 70% agreement), respectively. Each specimen demonstrated a response to at least one agent.
CONCLUSION: The evaluative power and reproducibility of HDRA were high, therefore it might serve as a reliable clinical method for chemosensitivity testing. However, there is a need for clinical trial in which patients are initially randomized for treatment either by HDRA direction or by clinician's choice.
|
|
KEYWORD
|
|
Breast neoplasm, Chemosensitivity test,
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|